Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01881789
Recruitment Status : Completed
First Posted : June 20, 2013
Last Update Posted : October 17, 2019
Sponsor:
Information provided by (Responsible Party):
Amgen

Tracking Information
First Submitted Date  ICMJE June 13, 2013
First Posted Date  ICMJE June 20, 2013
Last Update Posted Date October 17, 2019
Study Start Date  ICMJE August 2013
Actual Primary Completion Date September 23, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 16, 2015)
  • Maximum Tolerated Dose (MTD) [ Time Frame: 6 months ]
    For each dosing schedule, the MTD will be defined as the highest dose at which a DLT is observed in fewer than 2 of 6 patients. DLT is defined as any of the following treatment-related events occurring in the first 28 days of treatment.
  • Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: 36 months ]
    Safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide, as defined by the type, incidence, severity, and outcome of Adverse Events (AEs).
  • Overall Response Rate (ORR) [ Time Frame: 14 months ]
    The antitumor activity of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide, as measured by overall response rate (ORR).
  • Complete Response Rate (CRR) [ Time Frame: 17 months ]
    The antitumor activity of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide, as measured by complete response rate (CRR).
Original Primary Outcome Measures  ICMJE
 (submitted: June 17, 2013)
  • To establish the maximum tolerated dose (MTD) of oprozomib administered orally in combination with lenalidomide and dexamethasone [ Time Frame: 6 months ]
  • To estimate the overall response rate (ORR) [ Time Frame: 14 months ]
  • To estimate the complete response rate (CRR) [ Time Frame: 17 months ]
Change History Complete list of historical versions of study NCT01881789 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 16, 2015)
  • Population Pharmacokinetic (PK) Parameters - Apparent Clearance [ Time Frame: 18 months ]
    The Apparent Clearance is defined as the amount of drug administered (dose) divided by the plasma concentration-time curve (AUC) of oprozomib and its metabolites at various time points.
  • Population Pharmacokinetic (PK) Parameters - Volume of Distribution [ Time Frame: 18 months ]
    The Volume of Distribution is defined as the amount of oprozomib administered (dose) divided by initial oprozomib plasma concentration.
  • Duration of Response (DOR) [ Time Frame: 42 months ]
    Duration of Response is defined as the time from first evidence of partial response (PR) or better to confirmation of disease progression or death due to any cause.
  • Progression-Free Survival (PFS) [ Time Frame: 42 months ]
    Progression-Free Survival is defined as the time from the start of treatment to disease progression or death (due to any cause), whichever comes first.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 17, 2013)
  • To evaluate the safety and tolerability of oprozomib administered in combination with lenalidomide and dexamethasone [ Time Frame: 36 months ]
    Evaluated by number of participants with adverse events
  • To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with lenalidomide and dexamethasone [ Time Frame: 18 months ]
    Based on plasma concentration of oprozomib and its metabolites at various time points
  • To estimate the duration of response (DOR) [ Time Frame: 42 months ]
  • To estimate progression-free survival (PFS) [ Time Frame: 42 months ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Official Title  ICMJE Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Brief Summary

Phase 1b:

  • To establish the maximum tolerated dose (MTD) of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide
  • To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide

Phase 2:

  • To estimate the overall response rate (ORR) and complete response rate (CRR)
  • To evaluate the safety and tolerability of oprozomib and dexamethasone administered in combination with lenalidomide or oral cyclophosphamide

Secondary Objectives:

  • To evaluate population pharmacokinetic (PK) parameter estimates of oprozomib and variability in these estimates when administered in combination with dexamethasone and lenalidomide or oral cyclophosphamide
  • To estimate the duration of response (DOR)
  • To estimate progression-free survival (PFS)
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Multiple Myeloma
Intervention  ICMJE
  • Drug: Oprozomib
    Subjects will receive Oprozomib extended release (ER) Tablets (hereafter referred to as oprozomib) administered orally, once daily on 1, 2, 8, 9, 15,16, 22 and 23 of 28-day cycles
    Other Name: Oprozomib ER tablets
  • Drug: Lenalidomide
    Subjects will receive lenalidomide 25 mg on Days 1-21 of 28 day cycles
    Other Name: Revlimid
  • Drug: Dexamethasone
    Subjects will receive dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28 day cycles
  • Drug: Cyclophosphamide
    Subjects will receive cyclophophamide 300 mg/m2 on Days 1, 8 and 15 of 28 day cycles
    Other Name: Cytoxan
Study Arms  ICMJE
  • Experimental: Oprozomib, Lenalidomide and Dexamethasone (ORd)
    Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15,16, 22 and 23 in combination with lenalidomide at a dose of 25 mg on Days 1-21, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles.
    Interventions:
    • Drug: Oprozomib
    • Drug: Lenalidomide
    • Drug: Dexamethasone
  • Experimental: Oprozomib, Cyclophosphamide and Dexamethasone (OCyd)
    Subjects will receive oprozomib administered orally, once daily on Days 1, 2, 8, 9, 15, 16, 22 and 23 in combination with oral cyclophosphamide at a dose of 300 mg/m2 on Days 1, 8, and 15, and dexamethasone at a dose of 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28-day cycles
    Interventions:
    • Drug: Oprozomib
    • Drug: Dexamethasone
    • Drug: Cyclophosphamide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 8, 2019)
22
Original Estimated Enrollment  ICMJE
 (submitted: June 17, 2013)
59
Actual Study Completion Date  ICMJE September 23, 2019
Actual Primary Completion Date September 23, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Newly diagnosed, symptomatic multiple myeloma patients for whom treatment is indicated per the NCCN guidelines, and for whom a hematopoietic stem cell transplant is not planned or scheduled during the study or are considered ineligible for hematopoietic stem cell transplant, with measurable disease
  • Creatinine clearance of ≥ 50 mL/min (measured or calculated using the Cockcroft and Gault formula)

Key Exclusion Criteria:

  • Any prior systemic antimyeloma therapy except oral steroids (dexamethasone up to a total dose of 160 mg or equivalent within 14 days prior to the first dose of study treatment). Use of topical or inhaled steroids is acceptable
  • Radiation therapy within 2 weeks prior to first dose
  • Major surgery within 3 weeks prior to first dose
  • Active infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to first dose
  • Clinical significant gastrointestinal bleeding in the 6 months prior to Cycle 1 Day 1 (C1D1) first dose
  • Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of first dose
  • Other malignancy within the past 3 years except those considered cured by surgical resection including some cases of: with the exception of adequately treated basal or squamous cell carcinoma of the skin, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the breast or cervix, carcinoma in situ of the breast, prostate cancer with Gleason Score 6 or less with stable prostate specific antigen levels., or cancer considered cured by surgical resection
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01881789
Other Study ID Numbers  ICMJE OPZ003
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Amgen
Study Sponsor  ICMJE Amgen
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: MD Amgen
PRS Account Amgen
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP